Neihulizumab Uses, Dosage, Side Effects and more
Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.
| Attribute | Details |
|---|---|
| Trade Name | Neihulizumab |
| Generic | Neihulizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
